XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, released an update on its 2021 drug formulation programs, noting that the programs are advancing on schedule and expanding in scope. The company’s Rotigotine transdermal human pilot study was successfully completed in March and the program now advancing to a pivotal study stage; the pilot study evaluated the use of the Rotigotine transdermal patch in the treatment for Parkinson’s disease. In addition, the update noted that XPhyto had purchased land in Germany for the construction of its commercial drug manufacturing facility in Germany. The company’s drug formulation and development projects are conducted primarily by XPhyto’s wholly owned German subsidiary, Vektor Pharma TF GmbH, a company focused on the development of generic and hybrid-generic drug formulations for neurological conditions through its transdermal and oral dissolvable drug delivery platforms. “Vektor continues to build shareholder value by advancing its product development pipeline,” said XPhyto CEO & Director Hugh Rogers in the press release. “Its lead program is now progressing to a pivotal human study in Europe, which is the final major milestone on the path to commercial regulatory approval. The addition of in-house, scalable commercial drug manufacturing capability is expected to add further value and optionality to XPhyto’s drug formulation and manufacturing businesses.”
To view the full press release, visit https://ibn.fm/8uVS4
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork